List of accepted late-breaking abstracts

#EASLCongress easlcongress.eu
LB24
Efficacy and safety of HSK31679, a thyroid hormone receptor β agonist, for the treatment of asian nonalcoholic fatty liver disease: a multicenter randomized, double-blind, placebo-controlled, phase 2a trial
Poster presentation
Presenter: Feng Xue

LB27
Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial
Poster presentation
Presenter: Michael Trauner

LB31
BRII-179 induced functional immune response, demonstrating potential to improve chronic hepatitis B functional cure
Poster presentation
Presenter: Zhiliang Gao

LB35
Role of early on-treatment serum hepatitis B virus RNA declines in the prediction of hepatocellular carcinoma risk in patients with chronic hepatitis B
Poster presentation
Presenter: Jian Sun

LB45
AZD2693, a potent PNPLA3 antisense oligonucleotide, decreases hepatic PNPLA3 mRNA and liver fat content in participants with presumed MASH and homozygous for the PNPLA3 148M risk allele
Poster presentation
Presenter: Rohit Loomba

LB46
A phase 1, double-blinded, randomized, placebo-controlled, multicenter global study evaluating the safety, tolerability, and antiviral activity of DF-006 in chronic hepatitis B, virologically-suppressed patients
Poster presentation
Presenter: Edward J. Gane

LB51
Targeting RuvBL1 hampers NASH-HCC progression by tipping the scale from mTOR-driven lipogenesis to AMPK-induced lipolysis
Poster presentation
Presenter: Alice Guida

LB73
Results of a phase 2b multicenter randomized trial of larsucosterol for the treatment of severe alcohol-associated hepatitis (AHFIRM trial)
Oral presentation
Presenter: Mitchell Shiffman

LB79
Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study
Poster presentation
Presenter: Kosh Agarwal

LB92
Efruxifermin significantly reduced liver fibrosis in MASH patients with F2–F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)
Oral presentation
Presenter: Reshma Shringarpure

LB104
Epidemiological trends and clinical impact of multidrug-resistant bacterial infections in patients with cirrhosis across Latin America: results from the ACLARA study
Poster presentation
Presenter: Juan Manuel Diaz

LB105
VETC predicts benefit of anti-angiogenic drugs in advanced HCC
Poster presentation
Presenter: Luca Di Tommaso

LB106
Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10,000 IU/mL: part 2 of the REEF-D study
Poster presentation
Presenter: Heiner Wedemeyer

LB110
Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic par
Poster presentation
Presenter: Tarik Asselah

LB113
First-in-human clinical result of a novel HBV-specific TCR T cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma (HCC)
Poster presentation
Presenter: Xueshuai Wan

LB120
Evidence of transplant benefit for patients with severe acute-on-chronic liver failure: Interim results of the CHANCE study
Poster presentation
Presenter: Rajiv Jalan

LB121
Current graft allocation policies underestimate the mortality of patients with severe acute-on-chronic liver failure on the transplant waiting list: interim results of the CHANCE study
Oral presentation
Presenter: Thierry Gustot

LB125
Assessing the diagnostic accuracy of ChatGPT-4 in the histopathological evaluation of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)
Poster presentation
Presenter: Luca Di Tommaso
Beneficial effects of autologous macrophage therapy on clinical outcomes in patients with compensated cirrhosis: extended follow-up data from a randomized controlled Phase 2 trial
Poster presentation
Presenter: Paul Brennan

LB127
A prospective, blinded, multicenter U.S. evaluation of a multi-analyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis
Oral presentation
Presenter: Shivani Mahajan

LB128
Shortened telomeres impact liver regeneration in mice
Poster presentation
Presenter: Michael Hu

LB136
Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial
Poster presentation
Presenter: David E. Jones

LB137
Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis
Poster presentation
Presenter: Arun J Sanyal

LB139
Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial
Oral presentation
Presenter: Jennifer Lai

LB145
Promising first-in-human, first-in-class, Phase 1B immunogenicity data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV functional cure
Poster presentation
Presenter: Edward J. Gane

LB146
Deciphering the role of mechanical forces in liver regeneration by a biomimetic liver regeneration chip
Poster presentation
Presenter: Yu Du

LB148
Preclinical proof of concept and discovery of siRNA therapeutics targeting CIDEB for metabolic dysfunction-associated steatohepatitis
Poster presentation
Presenter: Jianhua Zhang

LB152
Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis
Poster presentation
Presenter: Jose Fortea
LB162
A phase IIa basket clinical trial of allogeneic CD362-enriched umbilical cord-derived mesenchymal stromal cells (ORBCEL-CTM) in patients with primary sclerosing cholangitis and autoimmune hepatitis
Poster presentation
Presenter: Julian Yeh

LB165
GM-60106 (a peripheral 5HT2A antagonist) as a clinical candidate for metabolic dysfunction-associated steatohepatitis (MASH)
Poster presentation
Presenter: Jin Hee Ahn

LB167
Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis
Oral presentation
Presenter: Rohit Loomba

LB175
Liver-kidney crosstalk: the influence of hepatic oxalate release on kidney gluconeogenesis
Poster presentation
Presenter: Philipp Gabrys

LB176
Antibiotic-mediated microbiota depletion limits IgA-related fibrogenesis in metabolic dysfunction-associated steatohepatitis
Oral presentation
Presenter: Svenja Schuehle

LB181
The effect of precursors on extracellular nicotinamide adenine dinucleotide in plasma
Poster presentation
Presenter: Sue Easaw

LB186
Effect of elafibranor on pruritus in primary biliary cholangitis: symptom severity and quality of life measurements from the phase III ELATIVE® trial
Poster presentation
Presenter: Andreas E. Kremer

LB187
Azemiglitazone in combination with GLP1 agonists increases benefit and could preserve lean body mass
Poster presentation
Presenter: Jerry Colca

LB188
Efficacy of elafibranor in primary biliary cholangitis: results from the variable double-blind period of ELATIVE®, a randomised, placebo-controlled phase III trial
Poster presentation
Presenter: Christopher L. Bowlus

LB189
Relationship between steatotic liver disease, all-cause mortality and cardiovascular related outcomes - 20 year follow up of a longitudinal cohort study
Poster presentation
Presenter: Oyekoya Ayonrinde

LB192
Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort
Poster presentation
Presenter: Francesca Terracciani

LB194
Use of tocilizumab for the treatment of steroid and mycophenolate-refractory hepatitis and cholangiohepatitis induced by immune checkpoint inhibitor immunotherapy
Poster presentation
Presenter: Sophia Ling

LB195
Preclinical safety data for PBGENE-HBV gene editing program supports advancement to clinical trials as a potentially curative treatment for chronic hepatitis B
Poster presentation
Presenter: Cassandra Gorsuch

LB196
Novel DGAT2 antisense inhibitor demonstrates significant MASH resolution in biopsy-proven F2/F3 MASH: results from a 51-week multicenter randomized double-blind placebo-controlled phase 2 trial
Oral presentation
Presenter: Rohit Loomba

LB212
Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study
Poster presentation
Presenter: Francesca Colapietro

LB213
Metabolic flux analysis using a 14C microtracer approach combined with accelerator mass spectrometry analysis - a proof of concept study on de novo lipogenesis
Poster presentation
Presenter: Martine C. Morrison

LB218
Liver-infiltrating activated HBV-specific tissue-resident memory T cells and atypical memory B cells were correlated with acute-on-chronic liver failure
Poster presentation
Presenter: Yang Cheng

LB235
Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH
Poster presentation
Presenter: Wen-Wei Tsai

LB242
Streamlined serodiagnosis of hepatitis delta: a novel lateral flow assay kit for on-site rapid diagnostics
Poster presentation
Presenter: Arghun Dashdorj
LB249
Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B
Poster presentation
Presenter: Edward J. Gane

LB250
Enhancing prediction of moderate fibrosis in MASLD patients for Resmetirom treatment via machine learning
Poster presentation
Presenter: Winston Dunn

LB253
Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH
Oral presentation
Presenter: Dean Tai

LB256
A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B
Poster presentation
Presenter: Wen Wang

LB259
Screening and comparison of current clinical candidates in MASH using human 3D liver spheroids
Poster presentation
Presenter: Francisco Verdeguer

LB265
Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
Oral presentation
Presenter: Rohit Loomba

LB266
Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial
Poster presentation
Presenter: Sebastian Meyhöfer

LB269
Evaluation of the PIKfyve kinase inhibitor Apilimod against hepatitis E virus infections
Poster presentation
Presenter: Julian Ring

LB270
Expression of inflammatory markers in cholangiocyte organoids from patients with primary sclerosing cholangitis recapitulate disease severity
Poster presentation
Presenter: Philip Puchas

LB273
AAV8 gene therapy for mitochondrial neurogastrointestinal encephalomyopathy
Poster presentation
Presenter: Teresa Brevini
LB274
Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies
Poster presentation
Presenter: Quentin M. Anstee

LB276
Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B - interim data of the OSPREY study
Poster presentation
Presenter: Stefan Bourgeois

LB283
Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interim results for 2 years from the ASSURE study
Poster presentation
Presenter: Palak J. Trivedi

LB292
Luji-1 reduces fibrosis by blocking Neuroligin-4 and β-neurexin and overexpressing thyroid hormone receptor-b, suggesting Rezdiffra sensitization and synergism in combination
Poster presentation
Presenter: Rifaat Safadi

LB294
15-year liver outcomes after metabolic surgery in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH)
Oral presentation
Presenter: Ali Aminian

LB296
Steatotic liver disease classification is highly dynamic impacting eligibility for clinical trials and subclass-specific interventions
Oral presentation
Presenter: Mads Israelsen

LB305
Performance of AASLD, AGA, AACE guidelines to identify patients for resmetirom treatment: pooled dataset including more than 4,000 patients with liver biopsy
Poster presentation
Presenter: Julie Dubourg

LB306
Characterization of immune cell populations in the microenvironment of mice liver during the progression of liver fibrosis to hepatocellular carcinoma
Poster presentation
Presenter: Ananya Ajith

LB307
Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH)
Poster presentation
Presenter: Zobair Younossi
LB309
Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing Phase 3 study, MYR301
Poster presentation
Presenter: Pietro Lampertico

STC316
Global subjective assessment and global leadership initiative on malnutrition as predictors of mortality in patients with cirrhosis
Poster presentation
Presenter: Loghman Salimzadeh